Heterocyclic compound for inducing degradation of mutant KRAS protein

Abstract

Provided is a compound useful as an active ingredient in a pharmaceutical composition for treating pancreatic cancer.　The present inventors carried out investigations with regard to compounds useful as an active ingredient in a pharmaceutical composition for treating pancreatic cancer and have found that a heterocyclic compound represented by formula (I) has an excellent action with regard to inducing the degradation of mutant KRAS protein and particularly with regard to inducing the degradation of G12V mutant, G12D mutant, and G12C mutant KRAS proteins, and has a mutant KRAS inhibitory activity and particularly G12V mutant, G12D mutant, and G12C mutant KRAS inhibitory activities. The present invention was achieved on the basis of these findings. The heterocyclic compound according to the present invention or a salt thereof can be used as a therapeutic agent for pancreatic cancer.

Images